Cerevel Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing new treatments for neuroscience diseases. Founded in late 2018 through a partnership with Pfizer and Bain Capital, Cerevel leverages a deep understanding of brain biology and neurocircuitry—how different parts of the brain communicate with each other—to create innovative therapies. The company is headquartered in Cambridge, Massachusetts.

Cerevel focuses on some of the most challenging and devastating neuroscience diseases, aiming to provide new treatment options for the hundreds of millions of people affected worldwide. These diseases include conditions like Parkinson's disease, epilepsy, and schizophrenia, among others. The company’s approach involves combining advanced chemistry with central nervous system (CNS) receptor pharmacology, which is the study of how drugs interact with specific receptors in the brain.

Cerevel operates in the biopharmaceutical market, specifically targeting neuroscience. Its business model revolves around research and development (R&D) to discover and develop new drugs. As a clinical-stage company, Cerevel does not yet have products on the market but is in the process of conducting clinical trials to test the safety and efficacy of its drug candidates. The company makes money primarily through funding from partnerships, investments, and grants, which support its R&D activities.

Cerevel's clients are primarily healthcare providers, researchers, and eventually, patients who will benefit from its therapies once they are approved. The company aims to transform what is possible in neuroscience by making intentional, rigorously evaluated decisions to deliver innovation.

Keywords: neuroscience, biopharmaceutical, clinical-stage, brain biology, neurocircuitry, CNS receptor pharmacology, Parkinson's, epilepsy, schizophrenia, drug development.